文献速递临床生化临床免疫

基于尿醛固酮检测的原发性醛固酮增多症诊断策略

A diagnostic strategy for primary aldosteronism diagnosis based on urinary aldosterone assay.
PubMed 文献 · Clin Chem Lab Med · 2026-09-01

该前瞻性研究纳入705例高血压住院患者(105例PA,600例原发性高血压),比较化学发光免疫分析法(cCLIA和sCLIA)与液相色谱-串联质谱(LC-MS/MS)检测24小时尿醛固酮排泄量的相关性和诊断效能,并评估基于直接肾素浓度(DRC)分层的解读策略。结果显示CLIA与LC-MS/MS强相关,AUC无显著差异,DRC分层可能支持方法特异性解读,但阈值需外部验证。

要点

  • CLIA法检测24小时尿醛固酮与LC-MS/MS强相关且诊断AUC无显著差异。
  • DRC分层( cutoff 8.1 mU/L)可能支持方法特异性解读尿醛固酮结果。
  • 所提出的阈值需前瞻性外部验证后方可用于临床。

核心结论

  • 基于CLIA的24小时尿醛固酮检测与LC-MS/MS强相关、平均偏差小,在本队列中诊断区分度相似。
  • DRC分层可能支持24小时尿醛固酮的方法特异性解读,但所提阈值需前瞻性外部验证后方可临床实施。

研究设计与样本

  • 前瞻性纳入705例高血压住院患者,其中PA 105例,原发性高血压600例。
  • 采用cCLIA、sCLIA和LC-MS/MS检测24小时尿醛固酮,CLIA检测DRC。
  • 方法一致性用Passing-Bablok回归和Bland-Altman分析评估,诊断性能用ROC评估,并以1000次结局分层bootstrap重抽样进行内部验证。

主要发现

  • cCLIA和sCLIA与LC-MS/MS的Spearman相关系数分别为0.946和0.950。
  • cCLIA、sCLIA和LC-MS/MS的总体AUC分别为0.809、0.814和0.812,方法间无统计学显著差异。
  • 低DRC亚组(≤8.1 mU/L)AUC分别为0.880、0.879和0.881;高DRC亚组(>8.1 mU/L)AUC分别为0.871、0.878和0.859。
  • 乐观校正后的AUC与原始估计接近。

关键数值与推荐

  • DRC cutoff 8.1 mU/L用于定义低DRC(≤8.1 mU/L)和高DRC(>8.1 mU/L)亚组。
  • 采用方法特异的高灵敏度和高特异度阈值构建探索性DRC分层解读策略。

临床怎么用

  • CLIA法检测24小时尿醛固酮可作为PA诊断的可行选择,但解读时需考虑DRC分层。
  • 所提出的DRC分层阈值在临床实施前需前瞻性外部验证。

局限性

  • 所提出的阈值需前瞻性外部验证后方可用于临床。
  • 研究为探索性策略构建,内部验证采用bootstrap重抽样。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare 24-h urinary excretion of aldosterone (24-h UEA) measured by competitive chemiluminescent immunoassay (cCLIA) and sandwich chemiluminescent immunoassay (sCLIA) with liquid chromatography-tandem mass spectrometry (LC-MS/MS), and to evaluate a direct renin concentration (DRC)-stratified interpretive strategy for primary aldosteronism (PA). METHODS: We prospectively enrolled 705 hypertensive inpatients, including 105 with PA and 600 with essential hypertension. 24-h UEA was measured by cCLIA, sCLIA, and LC-MS/MS, and DRC was measured by CLIA. Method agreement was assessed using Passing-Bablok regression and Bland-Altman analysis. Diagnostic performance was evaluated using receiver operating characteristic (ROC), with internal validation by 1,000 outcome-stratified bootstrap resamples. RESULTS: Both CLIAs correlated strongly with LC-MS/MS (Spearman r=0.946 for cCLIA and 0.950 for sCLIA). Overall areas under the curve (AUCs) were 0.809, 0.814, and 0.812 for cCLIA, sCLIA, and LC-MS/MS, respectively, with no statistically significant differences among the methods. A DRC cutoff of 8.1 mU/L was used to define low-DRC (≤8.1 mU/L) and high-DRC (>8.1 mU/L) subgroups. In the low-DRC subgroup, AUCs were 0.880, 0.879, and 0.881; in the high-DRC subgroup, they were 0.871, 0.878, and 0.859, respectively. Optimism-corrected AUCs remained close to the original estimates. Method-specific high-sensitivity and high-specificity thresholds were used to construct an exploratory DRC-stratified interpretive strategy. CONCLUSIONS: CLIA-based 24-h UEA measurements showed strong correlation and small mean bias with LC-MS/MS and similar diagnostic discrimination in this cohort. DRC stratification may support method-specific interpretation of 24-h UEA, but the proposed thresholds require prospective external validation before clinical implementation.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Gao Z, Gao X, Cong H, et al. A diagnostic strategy for primary aldosteronism diagnosis based on urinary aldosterone assay. Clin Chem Lab Med. 2026. PMID: 42670711. doi:10.1515/cclm-2026-0865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。